Field-Practical Automated Battery for Assessing and Monitoring Cognitive

Award Information
Agency:
Department of Defense
Branch
Navy
Amount:
$99,997.00
Award Year:
2001
Program:
SBIR
Phase:
Phase I
Contract:
N00014-02-M-0060
Agency Tracking Number:
O012-0332
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street, Suite 200, Austin, TX, 78701
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
001021042
Principal Investigator:
John Bruno
Chief Technical Officer
(512) 479-7732
bruno@spec.com
Business Contact:
Donald Gorsuch
President
(512) 479-7732
gorsuch@spec.com
Research Institution:
n/a
Abstract
OmniSite BioDiagnostics Inc. (OmniSite) proposes to aid in the field diagnosis of soft tissue injuries of DOD troops by development of DNA aptamer-based assays for protein markers and hydroxylated amino acids in diluted whole blood. DNA aptamers arenovel, inexpensive replacement reagents for antibodies that do not require animal hosts for production and are therefore inexpensive and simple to produce. In phase I, OmniSite will focus its assay development efforts on skeletal Troponin I (sTnI),creatine kinase isoform MM1 (CK-MM1), carbonic anhydrase III (CA III), hydroxylysine and hydroxyproline. This panel of candidate markers for soft tissue injury will be simultaneously analyzed in OmniSite's partitioned microfluidic cartridge byfluorescence polarization (FP). FP provides rapid, highly sensitive and accurate one-step binding assays without the need for wash steps. OmniSite has an intellectual property position, which allows miniaturization of FP into an inexpensive handheldreader format. The fusion of these powerful technologies will provide the DOD with facile and reliable field assays for soft tissue injuries. In Phase II, OmniSite will sequence the DNA aptamers, refine the FP-aptamer assays and deliver an FP readerprototype with model assays for testing. If successful, OmniSite will have an assay system that numerous point-of-care facilities may desire to aid in diagnosis of soft tissue injuries or cardiac infarctions for the general public.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government